Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
Phase II Trial of Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
Sponsor: ISA Pharmaceuticals B.V.
Terminated
Closed the trial for infeasibility due to slow accrual
Listed as NCT03258008, this PHASE2 trial focuses on Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites and Malignant Neoplasms of Lip Oral Cavity and Pharynx and remains terminated or withdrawn. Sponsored by ISA Pharmaceuticals B.V., it has been updated 12 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Jul 2022 — Jan 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — May 2018 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ISA Pharmaceuticals B.V.
- M.D. Anderson Cancer Center
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .